Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer

Published:2014-07-16 Issue:7 Volume:9 Page:e102777
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Li Ning,Yang Lu,Ou Wei,Zhang Liang,Zhang Song-liang,Wang Si-yu

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference34 articles.

1. Global cancer statistics;A Jemal;CA: a cancer journal for clinicians,2011

2. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group;FV Fossella;J Clin Oncol,2000

3. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;FA Shepherd;J Clin Oncol,2000

4. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;N Hanna;J Clin Oncol,2004

5. Erlotinib in previously treated non-small-cell lung cancer;FA Shepherd;The New England journal of medicine,2005

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continuation of immunotherapy beyond progression is beneficial to the survival of advanced non-small-cell lung cancer;Clinical and Translational Oncology;2023-12-25

2. Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients;BMC Cancer;2021-11-15

3. Epidermal growth factor receptor mutated lung cancers: Looking beyond adenocarcinomas;Indian Journal of Cancer;2020

4. Erlotinib en 2e ou 3e ligne pour les cancers bronchiques non à petites cellules sans mutation de l’EGFR : données en vie réelle;Revue des Maladies Respiratoires;2019-06

5. Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update;South Asian Journal of Cancer;2019-01